Skip to main content
BNTX logo

BNTX

BioNTech SE Sponsored ADR

$83.24

1.91%

Trade Ideas Performance

Latest Closed Trade Idea

$83.24

1.91%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

14

Social

9

About

Events of BioNTech SE Sponsored ADR (BNTX)

Over the past six months, BioNTech's stock (BNTX) experienced fluctuations influenced by several key events: In August 2026, BioNTech reported sharply lower Q2 2026 COVID-19 revenues and wider losses, leading to a cut in full-year guidance, though it highlighted substantial cash reserves and 14 pivotal oncology trials as future growth drivers. New EU authorization for a 2026-2027 XFG-adapted COVID-19 vaccine with Pfizer in August 2026 helped maintain a seasonal revenue stream. A leadership transition was announced in August 2026, with Guido Oelkers set to replace founder-CEO Ugur Sahin by 2027, signaling a strategic shift towards a diversified oncology and biopharma platform. In November 2026, BioNTech reported Q3 2026 results that surpassed analyst expectations for both earnings and revenue, despite a 15% year-over-year decline in revenue due to lower COVID-19 vaccine demand, leading to a raised full-year 2026 revenue guidance midpoint to €1.7-1.9 billion. Oncology pipeline advancements were highlighted in October-November 2026, including encouraging global Phase 2 data for pumitamig in advanced NSCLC, the advancement of a global Phase 3 clinical trial for pumitamig in combination with sacituzumab govitecan in triple-negative breast cancer, and data showing gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small cell lung cancer. However, a Phase II trial of autogene cevumeran for colorectal cancer was discontinued in November 2026 due to a numerical imbalance in overall survival. Additionally, the Phase III trial of trastuzumab pamirtecan in hormone receptor-positive, HER2-low metastatic breast cancer met its primary endpoint with a statistically significant but modest improvement in progression-free survival, though a higher rate of interstitial lung disease was reported in November 2026. As of November 2, 2026, the share price was $87.48, representing a decline of 16.55% from November 4, 2025, and an 18.30% change over the past year, with a 52-week range between $79.52 and $124.00.

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)